摘要
目的探讨早期使用替罗非班桥接拜阿司匹林和氯吡格雷双联抗血小板治疗急性脑梗死的疗效及安全性。方法选取我院(2017年1月至2019年1月)收治的110例急性脑梗死患者,根据不同治疗分为两组,对照组(n=55)接受氯吡格雷和拜阿司匹林治疗,观察组(n=55)接受替罗非班桥接双联抗血小板治疗,对比两组患者治疗前后神经功能缺损程度和生活能力以及预后情况(脑出血、全身性出血、3个月内死亡)。结果观察组治疗前NIHSS评分(13.16±2.11),对照组治疗前(13.15±2.10),治疗前两组患者NIHSS评分对比无差异(t=0.0249,P>0.05);治疗后3 d、15 d观察组NIHSS评分分别为(10.21±2.30)、(7.21±2.40),对照组评分分别为(11.25±2.41)、(9.25±2.34),两组患者NIHSS评分均明显下降,观察组改善更为明显(t=2.3152、4.5135,P<0.05)。观察组治疗前ADL评分(34.51±9.54),对照组为(34.50±9.55),治疗前两组患者ADL评分对比无差异(t=0.0055,P>0.05);治疗后3 d、15 d,观察组ADL评分分别为(45.71±9.65)、(56.57±9.45),对照组分别为(40.57±9.25)、(47.58±9.70),治疗后两组患者ADL评分均明显提升,观察组改善更为明显(t=2.8517、4.9232,P<0.05)。观察组脑出血、全身性出血、3个月内病死率分别为1例(1.82%)、4例(7.27%)、1例(1.82%),对照组分别为1例(1.82%)、3例(5.45%)、1例(1.82%),两组患者预后情况对比无差异(P>0.05)。结论替罗非班桥接拜阿司匹林和氯吡格雷双联抗血小板治疗急性脑梗死安全且有效。
Objective To explore the efficacy and safety of early tirofiban bridging aspirin and clopidogrel in the treatment of acute cerebral infarction.Methods 110 patients with acute cerebral infarction treated in our hospital(January 2017-January 2019)were selected and divided into two groups according to different treatments.The control group(n=55)received clopidogrel and Bayer aspirin.The group(n=55)received tirofiban bridging dual antiplatelet therapy,and the degree of neurological deficits,viability,and prognosis(cerebral hemorrhage,systemic bleeding,death within 3 months)were compared between the two groups of patients before and after treatment.Results The NIHSS score before treatment was(13.16±2.11)in the observation group and(13.15±2.10)before treatment in the control group.There was no difference in the NIHSS score between the two groups of patients before treatment(t=0.0249,P>0.05).The NIHSS scores of the observation group were 3 days and 15 days after treatment,respectively.The scores were(10.21±2.30),(7.21±2.40),and the control group scores were(11.25±2.41),(9.25±2.34),respectively.The NIHSS scores of the two groups were significantly decreased,and the improvement of the observation group was more significant(t=2.3152,4.5135,P<0.05).The ADL score of the observation group before treatment was(34.51±9.54),and the control group was(34.50±9.55).There was no difference in the ADL score between the two groups of patients before treatment(t=0.0055,P>0.05).At 3 and 15 days after treatment,the ADL score of the observation group was(45.71±9.65),(56.57±9.45),and the control group were(40.57±9.25),(47.58±9.70),respectively.After treatment,the ADL scores of the two groups were significantly improved,and the improvement of the observation group was more significant(t=2.8517,4.9232,P<0.05).Cerebral hemorrhage,systemic hemorrhage,and mortality within 3 months were 1 case(1.82%),4 cases(7.27%),and 1 case(1.82%)in the observation group,and 1 case(1.82%)and 3 cases(5.45%)in the control group.1 case(1.82%),there was
作者
王庆月
WANG Qing-yue(People's Hospital of Yanggu County,Liaocheng 252300,China)
出处
《中国医药指南》
2020年第12期18-20,共3页
Guide of China Medicine
